Supplementary Table 3. Baseline characteristics among individuals stratified by ABCD-GENE score (<10 or ≥10)

Characteristics	ABCD-GENE score* <10		ABCD-GENE score* ≥10	
	Aspirin (n=1,915)	Clopidogrel-aspirin (n=1,849)	Aspirin (n=458)	Clopidogrel-aspirin (n=471)
Age (yr)	65.0 (57.0–70.0)	64.0 (57.0–70.0)	68.0 (59.0–76.0)	68.0 (59.0–76.0)
Male sex	1,197 (62.5)	1,225 (66.3)	274 (59.8)	289 (61.4)
Body mass index (kg/m^2)	24.5 (22.7–26.4)	24.4 (22.6–26.3)	24.7 (22.3–27.9)	24.4 (22.5–27.8)
Medical history				
Hypertension	1,276 (66.6)	1,248 (67.5)	314 (68.6)	333 (70.7)
Diabetes mellitus	511 (26.7)	490 (26.5)	145 (31.7)	141 (29.9)
Dyslipidemia	74 (3.9)	56 (3.0)	22 (4.8)	20 (4.2)
Previous ischemic stroke	576 (30.1)	544 (29.4)	138 (30.1)	137 (29.1)
Current smoking	558 (29.1)	551 (29.8)	100 (21.8)	124 (26.3)
Use of agents before qualifying event				
Aspirin	247 (12.9)	232 (12.5)	74 (16.2)	55 (11.7)
Clopidogrel	7 (0.4)	14 (0.8)	3 (0.7)	2 (0.4)
Lipid-lowering agent	181 (9.5)	179 (9.7)	53 (11.6)	39 (8.3)
Qualifying event				
TIA	247 (12.9)	237 (12.8)	57 (12.4)	53 (11.3)
Acute single infarction	366 (19.1)	361 (19.5)	106 (23.1)	88 (18.7)
Acute multiple	1,302 (68.0)	1,251 (67.7)	295 (64.4)	330 (70.1)
≥50% symptomatic stenosis				
Yes	1,539 (81.9)	1,492 (82.0)	377 (84.5)	380 (82.4)
No	340 (18.1)	328 (18.0)	69 (15.5)	81 (17.6)
NIHSS score in qualifying ischemic stroke†				
≤3	1,308 (78.4)	1,266 (78.5)	300 (74.8)	325 (77.8)
4 or 5	360 (21.6)	346 (21.5)	101 (25.2)	93 (22.2)
ABCD^2 score in qualifying TIA‡				
4 or 5	186 (75.3)	192 (81.0)	43 (75.4)	45 (84.9)
>5	61 (24.7)	45 (19.0)	14 (24.6)	8 (15.1)
Statin therapy§				
Immediate intensive statin	951 (49.7)	912 (49.3)	238 (52.0)	240 (51.0)
Delayed intensive statin	964 (50.3)	937 (50.7)	220 (48.0)	231 (49.0)
CYP2C19 LOF carriers				
No LOF allele	1,005 (52.5)	954 (51.6)	5 (1.1)	5 (1.1)
One LOF allele (intermediate metabolizer)	910 (47.5)	895 (48.4)	173 (37.8)	175 (37.2)
Two LOF alleles (poor metabolizer)	0 (0.0)	0 (0.0)	280 (61.1)	291 (61.8)

Values are presented as median (interquartile range) or n (%).

TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; ABCD^2, age, blood pressure, clinical features, duration of symptoms, and diabetes; LOF, loss-of-function.

*ABCD-GENE score was calculated by factors of age, body mass index, chronic kidney diseases, diabetes, and *CYP2C19* genotyping, which ranged from 0 to 34 (higher ABCD-GENE score indicating high platelet reactivity); †NIHSS score ranges from 0 to 42 for evaluating conditions of patients with ischemic stroke, and higher scores suggest more severe stroke; ‡ABCD^2 score ranges from 0 to 7, and higher scores suggest higher risk of stroke; §The immediate intensive statin and delayed intensive statin groups correspond to the factorial statin randomization arms of the Intensive Statin and Antiplatelet for Acute High-Risk Intracranial or Extracranial Atherosclerosis trial.